PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Kimberly Halla, MSN, FNP-C - Realizing the Promise of PARP Inhibitors in Solid Tumor Therapy: Guiding Oncology Nurses on the Advances and Challenges
Go online to PeerView.com/KWE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView MasterClass, an expert panel of oncology nurse professionals presents the highlights of emerging science and clinical data on PARP inhibition in multiple solid tumors, assesses the role of companion diagnostic tests that identify patients with DDR mutations, as well as engage the audience in a stimulating discussion on the value of genetic testing and significance of enrollment in ongoing PARP inhibitor clinical trials. Going beyond the standard didactic lectures, our experts share their own perspectives on best practice strategies to effectively and safely use approved and emerging PARP inhibitors within the framework of challenging case scenarios. Upon completion of this activity, participants will be able to: Describe DNA-damage response (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors as a cancer therapeutic strategy, Assess the clinical role, efficacy, and safety of PARP inhibitors in multiple tumor types, including ovarian, breast, pancreatic, and prostate cancers, across different treatment settings, Counsel patients receiving PARP inhibitor therapy on strategies to prevent and/or manage treatment emergent adverse events, Provide appropriate education and guidance to patients on the safe and effective clinical use of novel PARP inhibitors, including dosing, the need for adherence to therapy, and enrollment into clinical trials.